Abstract:The blood-brain barrier (BBB) has a key role in preventing drugs from entering the brain. Non-invasive intranasal drug delivery routes that bypass the BBB are increasing in popularity because of their ability to shorten the journey and reduce the loss of genetic drugs such as siRNA in transit. However, the com-plex synthesis and quality control process of most nose-to-brain delivery carriers and the limited mass production are the main obstacles to their clinical application. Here, we constructed a siRNA delivery system with simple synthesis and quality control methods using cholesterol-modified T7 (T7-C), in which T7 can bind to the transferrin receptor (TfR) expressed on glioma cells to target gliomas. In our results, T7-C had dual functions as a glioma-targeting carrier and immune adjuvant. As a targeted delivery car-rier, T7-C intranasally delivered siRNA into the mouse brain through the olfactory bulb pathway and was taken up by glioma cells by the caveolin-and transferrin-dependent pathway. As an immune adjuvant, T7-C could promote DC maturation and combined with slit2 siRNA could promote polarization of M2 subtype macrophages to M1 subtype macrophages and then increase the proportion of effector T cells to remodel the tumor environment. In conclusion, T7-C with glioma targeting as a delivery system of slit2 siRNA showed a good therapeutic effect in the treatment of glioma after intranasal administration and had potential application prospects.Statement of significanceIn contrast to the existing literature that uses complex materials to deliver drugs across the blood-brain barrier (BBB) in an invasive manner for glioma treatment, we developed a simple, self-assembling siRNA delivery system (T7-C) based on brain tumor-targeted T7 peptide to treat glioma by intranasal administra-tion. T7-C/siRNA could reach the tumor site through the olfactory bulb route and adjust the "cold" tumor microenvironment to the "hot" tumor microenvironment and non-invasive intranasal delivery route could shorten the journey and reduce the loss of genetic drugs. Therefore, our design has good application prospects and is expected to serve as a general strategy for intranasal drug delivery in the treatment of brain tumors.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma

Spherical Nucleic Acid Nanoparticle Conjugates As an RNAi-Based Therapy for Glioblastoma*

Dual Bioluminescence and Near-Infrared Fluorescence Monitoring to Evaluate Spherical Nucleic Acid Nanoconjugate Activity in Vivo

Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy

Engineered smart materials for RNA based molecular therapy to treat Glioblastoma

Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment

Single-component self-assembled RNAi nanoparticles functionalized with tumor-targeting iNGR delivering abundant siRNA for efficient glioma therapy.

A Simple Self-Assembly Nanomicelle Based on Brain Tumor-Targeting Peptide-Mediated Sirna Delivery for Glioma Immunotherapy Via Intranasal Administration

Spherical Nucleic Acids-Based Nanoplatforms for Tumor Precision Medicine and Immunotherapy

Transforming Hairpin-like Sirna-Based Spherical Nucleic Acids into Biocompatible Constructs.

Enhanced Nose-to-brain Delivery of Sirna Using Hyaluronan-Enveloped Nanomicelles for Glioma Therapy

Polymer-lipid hybrid nanomedicines to deliver siRNA in and against glioblastoma cells

Therapeutic applications of spherical nucleic acids.

Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas.

Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma

Boosting RNAi Therapy for Orthotopic Glioblastoma with Nontoxic Brain-Targeting Chimaeric Polymersomes

Abstract IA16: Spherical Nucleic Acids As a Powerful New Platform for Cancer Immunotherapy

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

A Crosslinked Nucleic Acid Nanogel for Effective Sirna Delivery and Antitumor Therapy

Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities

A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma